Willliam K.J. Skinner

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/2dd29a80-b7d4-11ed-9653-8957fcc72790.jpg

First Name

Willliam

Last Name

Skinner

NPI

1407994155

Faculty ID

12801

CMO Specialties

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

178407

Biography

<p>William Skinner, MD, is an attending physician and Associate Professor at Montefiore Einstein. Dr. Skinner&rsquo;s clinical focus is in the diagnosis and treatment of prostate cancer, lung cancer and radiation immune reactions.</p><p>In 1996, Dr. Skinner completed his Bachelor of Science in biology at the U.S. Air Force Academy. He then attended the University of Virginia, earning his Doctor of Medicine in 2000. Dr. Skinner completed his postdoctoral training in radiation oncology at Montefiore Medical Center from 2006 to 2010.</p><p>Dr. Skinner&rsquo;s research focuses on the mitigation and prevention of radiation-induced injury and the interaction of radiation and the immune system. His research has been shared through peer-reviewed journals, oral presentations and poster presentations.</p><p>Dr. Skinner is a Diplomate of the American Board of Radiology. He is a member of the American Society of Therapeutic Radiation and Oncology, the American College of Radiology, the Radiation Research Society and the American Brachytherapy Society.</p>

Is Open Scheduling

Off

Johnny Yap

https://assets.montefioreeinstein.org/profiles/images/physphoto/Yap_Johnny_MD_420x504-2.jpg

First Name

Johnny

Last Name

Yap

NPI

1790766269

Faculty ID

17426

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Utilizing a broad range of radiation treatment technologies.

Research Focus

Breast cancer.

Elsevier Profile

EMR ID

113299

Biography

<p>Johnny Yap, MD, is a Radiation Oncologist and Assistant Professor, Radiation Oncology at Montefiore Einstein. With a clinical focus is in breast, gastrointestinal, gynecological, lung and stereotactic radiation, Dr. Yap has expertise with utilizing a broad range of radiation treatment technologies.</p><p>After earning his Doctor of Medicine at Rosalind Franklin University, Chicago Medical School in 1995, Dr. Yap completed his internship at Yale University in 1996, followed by his radiation oncology residency at Wayne State University Medical Center, Detroit Medical Center in 2000.</p><p>Dr. Yap&rsquo;s research interests focus on breast cancer. His work has been shared in peer-reviewed journals as well as posters, abstracts and oral presentations. Dr. Yap is also an editorial board member and reviewer for <em>Journal of Gastrointestinal Oncology</em>.</p><p>Dr. Yap is board certified by the American Board of Radiology and is a member of the American Society of Radiation Oncology and the Radiosurgery Society.</p>

Is Open Scheduling

Off

Marc Vimolratana

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/58a00310-6a8c-11ec-afc2-e529147b8d1e.jpg

First Name

Marc

Last Name

Vimolratana

NPI

1467870683

Faculty ID

17157

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Vimolratana is a general thoracic surgeon with a clinical focus on thoracic surgical oncology, including minimally invasive surgery for lung and esophageal cancer. His other clinical interests include mediastinal and chest wall tumors, tracheal disorders, thoracic outlet syndrome, and benign esophageal diseases.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Vimolratana&rsquo;s research focuses on improving patient outcomes after complex lung and esophageal surgery. He has shared his findings through publications in peer-reviewed journals and abstracts at national meetings.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

163553

Biography

<p>Marc Vimolratana, MD, MS, is Assistant Professor, Cardiothoracic and Vascular Surgery at Montefiore Einstein. Dr. Vimolratana is a general thoracic surgeon with a clinical focus on thoracic surgical oncology, including minimally invasive surgery for lung and esophageal cancer. His other clinical interests include mediastinal and chest wall tumors, tracheal disorders, thoracic outlet syndrome, and benign esophageal diseases. Dr. Vimolratana takes a patient-centered approach to patient care and is committed to using minimally invasive techniques, including VATS and robotic surgery, whenever possible to minimize surgical trauma and pain for patients.</p><p>Dr. Vimolratana studied chemistry at Yale, earning a Bachelor of Science and Master of Science in 2006. He attended medical school at the University of California, San Francisco, earning a Doctor of Medicine in 2014. After many years in California, he moved to New York for postdoctoral training at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, where he completed a residency in general surgery in 2019, serving as chief resident in his final year. Dr. Vimolratana continued at NewYork-Presbyterian Hospital for fellowship training in cardiothoracic surgery prior to joining the faculty at Montefiore Einstein in 2021.</p><p>Dr. Vimolratana&rsquo;s research focuses on improving patient outcomes after complex lung and esophageal surgery. He has shared his findings through publications in peer-reviewed journals and abstracts at national meetings.</p><p>Dr. Vimolratana is certified by the American Board of Thoracic Surgery and the American Board of Surgery. He is a member of several professional organizations, including the American College of Surgeons, the Society of Thoracic Surgeons and the European Society of Thoracic Surgeons. He has been honored with numerous awards for academic excellence and clinical care.</p>

Is Open Scheduling

Off

Brendon M. Stiles

https://assets.montefioreeinstein.org/profiles/images/Stiles_Brendon_MD_2x.jpg

First Name

Brendon

Last Name

Stiles

NPI

1013176387

Faculty ID

16884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNoSpacing">Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic &amp; Vascular Surgery at Montefiore-Einstein.&nbsp; Dr. Stiles is also the Associate Director for Surgical Services in the Montefiore-Einstein Cancer Center. Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.</p>
<p class="MsoNoSpacing">Dr. Stiles is also heavily involved with translational and basic research.&nbsp; Translationally, Dr. Stiles is interested in neoadjuvant immunotherapy and in predicting and augmenting response to immunotherapy.&nbsp; &nbsp;In the laboratory, he has been funded by the AATS, TSF, the Lung Cancer Research Foundation, the DOD CDMRP Lung Cancer Research Program, and the Mark Foundation.&nbsp;</p>
<p class="MsoNoSpacing">Dr. Stiles' laboratory currently investigates the protein ART1, an extracellular mono-ADP-ribosyltransferase.&nbsp; Recently, Dr. Stiles and his team discovered that ART1 may play an important role in one mechanism of resistance in lung cancers. ART1 mono-ADP-ribosylates the P2X7 receptor (P2X7R) on immune cells, which ultimately causes NAD-induced cell death (NICD) in T cells, macrophages, and dendritic cells. They found ART1 to be highly expressed in multiple human non-small cell lung cancer cell lines and in the majority of human lung adenocarcinomas they sampled.<span style="mso-spacerun: yes;">&nbsp; </span>ART1 expression allows cancers to blunt the immune response against them. Indeed, they found that inhibiting ART1 with a therapeutic monoclonal antibody in mouse models of lung cancer caused a dramatic reduction of tumor burden and an enrichment of immune cells in the tumor.</p>
<p class="MsoNoSpacing"><span style="font-size: 12pt;">Current efforts are underway to better understand regulation of ART1 expression, to identify more targets of extracellular mono-ADP-ribosylation, and to refine pre-clincal models to test their therapeutic antibody targeting ART1.</span></p>
<p class="MsoNoSpacing">&nbsp;</p>
<p class="MsoNoSpacing">&nbsp;</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.
</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.&nbsp; In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif;">Wennerberg, Erik et al, Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.&nbsp;&nbsp;<em>Science Translational Medicine.&nbsp;</em>2022 Mar 16;14(636):eabe8195.&nbsp;&nbsp;</span><u style="font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 14px;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; color: #0563c1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.s…;
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Altorki, Nasser K., et al. "The lung microenvironment: an important regulator of tumour growth and metastasis."&nbsp;</span><em style="font-size: 12pt;"><span style="font-family: Arial, sans-serif;">Nature Reviews Cancer</span></em><span style="font-size: 12pt;">&nbsp;19.1 (2019): 9-31.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Yao, Zhan, et al. "TGF-&beta; IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Proceedings of the National Academy of Sciences</span></em>&nbsp;107.35 (2010): 15535-15540.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Gao, Dingcheng, et al. "Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Cancer research</span></em>&nbsp;72.6 (2012): 1384-1394.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Altorki, Nasser K., et al. "Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">The Lancet Oncology</span></em>&nbsp;22.6 (2021): 824-835.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Wennerberg, Erik, et al. "Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">JOURNAL FOR IMMUNOTHERAPY OF CANCER</span></em>. Vol. 7. CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND: BMC, 2019.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Chen, Chuang, et al. "ART1, an extracellular ADP-ribosyltransferase, is over-expressed in non-small cell lung cancer and facilitates cancer cell survival by immune-mediated mechanisms."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Journal of Thoracic Oncology</span></em>&nbsp;11.2 (2016): S44.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">https://scholar.google.com/citations?user=fR4OkgkAAAAJ&amp;hl=en&amp;oi…;

EMR ID

82842

Biography

<p>Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic &amp; Vascular Surgery at Montefiore Einstein, and the Associate Director for Surgical Services in the Montefiore Einstein Cancer Center. Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.</p><p>&ldquo;The recruitment of&nbsp;Dr. Stiles elevates the treatment of lung cancer to a historic level,&rdquo; said Robert E. Michler, MD, Surgeon-in-Chief and Chairman and Professor, Department of Surgery and Department of Cardiothoracic &amp; Vascular Surgery at Montefiore-Einstein. &ldquo;Every thoracic surgical therapy available anywhere in the world will now be offered by Dr. Stiles at Montefiore-Einstein.&rdquo;</p><p>After earning his Bachelor of Arts in 1994 at the University of Virginia, Dr. Stiles continued at UVA, earning his Doctor of Medicine in 1999.&nbsp; He conducted his training in general surgery at the University of Virginia Health System. From 2001 to 2003, Dr. Stiles served as a surgical research fellow at Memorial Sloan-Kettering Cancer Center before returning to the University of Virginia Health System to complete his surgical residency. Dr. Stiles completed a cardiothoracic surgery residency at NewYork-Presbyterian Hospital-Weill Cornell and Memorial Sloan-Kettering Cancer Center in 2008. Dr. Stiles joined the faculty at NewYork-Presbyterian Hospital-Weill Cornell before being recruited by Dr. Michler to Montefiore-Einstein in 2021.</p><p>Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.&nbsp; In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer. In addition to publications in peer-reviewed journals, he has also given several invited national and international talks on his research and on the clinical management of lung and esophageal cancer.</p><p>Dr. Stiles is highly active in the lung cancer care community, having lost his own father to lung cancer in 2005. He is committed to raising money for lung cancer research, serving as chair of the Lung Cancer Research Foundation since 2017. He is also an invited member of the National Lung Cancer Roundtable and on the Lung-RADS Steering Committee for lung cancer screening with the American College of Radiology.&nbsp; Dr. Stiles is a member of several professional organizations including the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American Society of Clinical Oncology, the European Society of Thoracic Surgeons and the International Association for the Study of Lung Cancer.</p>

Is Open Scheduling

Off

Simon D. Spivack

https://assets.montefioreeinstein.org/profiles/images/Spivack_Simon_MD_2x.jpg

First Name

Simon

Last Name

Spivack

NPI

1366438475

Faculty ID

11003

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>&nbsp;</p>
<p>Focusing diagnostics and therapeutics on those most likely to benefit is a key to successful intervention&nbsp;at both the public health and clinical levels. The translational goal of the Spivack laboratory is to identify individuals at particularly high risk for lung malignancy, and selected non-malignant lung diseases, upon whom to focus smoking/toxin exposure cessation (primary prevention), chemoprevention (secondary prevention), and early disease detection efforts (disease screening, tertiary prevention).</p>
<p>The laboratory is currently exploring individual Gene x Environment signatures as susceptibility markers by exploring quantitative gene (mRNA) expression phenotypes, and the DNA sequence, methylation, microRNA, and other epigenetic features potentially underlying these expression phenotypes, <em>in vitro</em> and in human populations. This is performed in the setting of defined tobacco, diet, and other exposures. There are both mechanistic and translational components to the studies.&nbsp;</p>
<p><br /><strong>Mechanistically</strong>, the role of epigenetic variation in promoter regions in the 5' and 3' regulatory regions of carcinogenesis and oxidant pathway genes is being explored <em>in vitro</em>, using human genomic DNA reporter constructs, and native gene regulation models. High resolution technologies include the realtime quantitation of native mRNA and microRNA by the laboratory's RNA-specific strategy (<em>patented</em>); the&nbsp;tagged-bisulfite genomic sequencing strategy to determine single base resolution CpG methylation status (tBGS, <em>patented</em>);&nbsp;&nbsp;an experimental strategy for assaying microRNA binding to mRNA, for determining the role of miRNA in candidate gene regulation&nbsp;(<em>patented</em>); and evaluation of functional consequences of DNA&nbsp;methylation detail, using a novel patch reporter construct (<em>patented</em>).&nbsp; A new method to engineer methyl-cytosines into the epigenome has recently been developed.</p>
<p>Whole (epi)genome approaches to identify molecular events unique to lung cancer&nbsp;are being completed, which will represent one of the initial cross-platform 'omics level discovery examinations of&nbsp;lung&nbsp;tissues.&nbsp; The execution of each individual discovery platform involves&nbsp;expert local collaborators and cores&nbsp;in (epi)genetics and genomics, and the "integromics" is critically reliant on Einstein strengths in informatics and biostatistical analyses.</p>
<p>&nbsp;</p>
<p><strong>Translationally</strong>, human lung carcinogenesis biomarkers are being established by pairing laser capture microdissected lung with several unique, non-invasively collected surrogate specimens developed in the laboratory. These include mRNA expression signatures from brush-exfoliated buccal mucosa cells, microRNAs detected in exhaled breath condensate representing first reports for a new exhaled airway biomarker class, and exhaled metabolomic signatures. These airway-derived specimens continue to accrue from a sampling (currently n&gt;1000) of a population assembled in a lung cancer case-control context.&nbsp; The specimens are being studied with a view toward developing non-invasive assays in populations.</p>
<p>&nbsp;</p>
<p>The overall aim is to develop informative non-invasive risk profiling, preventive, and early disease detection strategies for the lung in human populations.</p>
<p>&nbsp;</p>
<p>&nbsp;<em>Work is funded by ongoing NIH,</em><em> DoD,&nbsp;and&nbsp;Foundation support.</em></p>
<p>&nbsp;</p>
<p><strong>Clinical Specialties</strong></p>
<ul style="font-size: 1em; color: #333333; padding: 0px; margin: 20px 0px 25px 38px;">
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung nodule evaluation</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung cancer diagnostics and screening</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">interstitial lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">environmental lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">refractory asthma</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">general pulmonary medicine</li>
</ul>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">A researcher and clinician, Dr. Spivack is developing tests for detecting lung cancer at the earliest possible stage&mdash;before it becomes fatal by spreading to other parts of the body. In one of several NIH-funded studies, his laboratory is working on a noninvasive, early-diagnosis test for lung cancer that detects particular genetic elements and chemicals in exhaled breath.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">In addition to general pulmonary medicine, Dr. Spivack&rsquo;s clinical practice focuses on lung nodule and lung cancer diagnosis, diffuse interstitial lung diseases, and environmental lung diseases.</span></p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease.<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;"><strong></strong></span>

Research Focus

Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans.

Elsevier Profile

Selected Publications

<p>&nbsp;</p>
<p><strong><span style="text-decoration: underline;">Selected Publications, as of April, 2023</span>:</strong></p>
<p class="MsoNormal"><span style="text-indent: -0.25in;">Shi M, Han W, Loudig O, Shah C, Dobkin J, Keller S, Sadoughi A, Patel D, Desai A, Gombar S, Suh Y, Fernandez MK, DeLaRosa L, Wang T, Hosgood D, Pradhan K, Ye K, </span><strong style="text-indent: -0.25in;">Spivack SD.</strong><span style="text-indent: -0.25in;">&nbsp; </span><span style="text-indent: -0.25in;">(2023) Initial development and testing of an exhaled microRNA detection strategy for lung cancer case-control discrimination</span><em style="text-indent: -0.25in;">. [accepted, Scientific Reports, NPG]</em></p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="color: #212121; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Huang Z, Sun S, Lee M, Maslov AY, Shi M, Waldman S, Marsh A, Siddiqui T, Dong X, Peter Y, Sadoughi A, Shah C, Ye K, *<strong>Spivack SD</strong>, *Vijg J. Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smoking. Nat Genet. 2022 Apr;54(4):492-498. doi: 10.1038/s41588-022-01035-w. Epub 2022 Apr 11. PMID: 35410377. (*co-senior authors).</span></p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
<p class="MsoNormal"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span><!--[endif]--><span lang="EN">Cleven KL, Ye K, Zeig-Owens R, Hena KM, Montagna C, Shan J, Hosgood HD 3rd, Jaber N, Weiden MD, Colbeth HL, Goldfarb DG, <strong>Spivack SD</strong>++, Prezant DJ++ (++co-senior authors). </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/31126090"><span lang="EN" style="color: windowtext; text-decoration-line: none;">Genetic Variants Associated with FDNY WTC-Related Sarcoidosis.</span></a><span lang="EN"> Int J Environ Res Public Health. 2019 May 23;16(10). pii: E1830. doi: 10.3390/ijerph16101830. PMID:31126090</span>.</p>
<p>Dong X, ShiN, LeeM, ToroR, Gravina S, Han W, Yasuda S, Wang T, Zhang Z, Vijg J, Suh Y, <strong>Spivack SD.</strong> (2018) Global, integrated analysis of methylomes and transcriptomes from laser capture microdissected bronchial and alveolar cells in human lung. <em>Epigenetics </em>10.1080/15592294.2018.1441650, 2018.</p>
<p>Mullapudi N, Ye B, Suzuki M, Wang T, Fazarri M,&nbsp;Han W, Shi M, Marquardt G, Lin J, Wang T,&nbsp;Keller S, Zhu C, Locker&nbsp;J, &nbsp;<strong>Spivack SD.</strong> Genome-wide methylome alterations in lung cancer&nbsp;<em> PLoS ONE, </em>Dec. 2015.</p>
<p>Lin J, Marquardt G, Mullapudi N,&nbsp;Wang, T,&nbsp;Han W, Shi W, Zhu C, Keller S,&nbsp;Zhu C,&nbsp;Locker J, <strong>Spivack SD. </strong>Lung cancer transcriptomes refined with laser capture microdissection.<em>&nbsp;Am J Pathology </em>06.028.&nbsp;2014 .</p>
<p>Han W, Shi M, <strong>Spivack SD</strong>. Site-specific methylated reporter constructs for functional analysis of DNA methylation.<em> Epigenetics </em>4; 8(11), 2013.</p>
<p>Shi M, Han W, <strong>Spivack SD</strong>. A quantitative method to identify miRNAs targeting an mRNA using a 3'UTR RNA affinity technique.<em> Analytic Biochem</em>&nbsp;1;443(1):1-12, 2013<em>.</em></p>
<p>Alberg AJ, Brock MV, Ford JG, Samet JM, <strong>Spivack, SD.</strong>&nbsp;&nbsp;Epidemiology of lung cancer.&nbsp; In Evidence-based Practice Guidelines. Diagnosis and Management of Lung Cancer (ACCP position statement). <em>CHEST</em>.&nbsp;&nbsp;May 2013;143(5 Suppl):e1S-e29S. doi: 10.1378/chest.12-2345. PMID: 23649439.</p>
<p>Tan XT, Marquardt G, Shi M, Han W, <strong>Spivack SD.</strong> High throughput library screening identifies phytochemical inducers of phase II mutagen/oxidant metabolism enzymes GSTP1 and NQO1 in human lung cells.<em> Am J Resp Cell Molec Biol, </em>46(3): 365-71, 2012.</p>
<p>Brock GJ,&nbsp;Moschos S, <strong>Sp</strong><strong>ivack SD,</strong> Hurteau GJ.&nbsp;The 3' prime paradigm of the miR-200 family and other microRNAs. <em>Epigenetics</em> (6:3, 1-5), 2011.</p>
<p>Tan XT, &nbsp;Shi M, &nbsp;Minna JD,&nbsp; Han W,&nbsp; <strong>Spivack SD.</strong> Candidate phytopreventive agent modulation of phase II metabolism enzymes <em>GSTP1</em> and <em>NQO1</em> in human bronchial cells<em>. J Nutrition,&nbsp;</em>140(8): 1404-10, 2010<em>.</em></p>
<p>Tan, XT, &nbsp;&nbsp;Wang T,&nbsp; Xiong S,&nbsp; Kumar SV,<strong>&nbsp;</strong> Han W, &nbsp;<strong>Spivack SD.</strong> &nbsp;Smoking-related gene expression in laser capture microdissected human lung. <em>Clin Cancer Res,</em> 15(24): 7562-70, 2009.</p>
<p>Han W, Tang T, Reilly AA, Keller S, <strong>Spivack SD</strong>. Gene promoter methylation analyses from exhaled breath, with differences in smokers and lung cancer cases.&nbsp; <em>Resp Res,</em> 10:86 epubl, 2009.</p>
<p>Tan X-L,&nbsp; Moslehi R, Han W, <strong>Spivack SD</strong>. Haplotype tagging single nucleotide polymorphisms in the glutathione S-transferase P1 gene promoter and susceptibility to lung cancer. <em>Cancer Detection Prev,</em>32:403-415, 2009<em>.</em></p>
<p>Tan X-L,&nbsp;&nbsp;<strong>Spivack SD</strong>. Dietary chemoprevention strategies for&nbsp;induction of phase II metabolism: a review. <em>Lung Cancer,</em>65(2):129-37, 2009.</p>
<p>Hurteau GJ, Carlson AJ, <strong>Spivack, SD,</strong> Brock GJ. Restoration of E-Cadherin expression by over-expression of the microRNA <em>hsa-miR-200c</em> via reduced expression of the transcription factor TCF8. <em>Cancer Res.</em> 67:7972-76, 2007.</p>
<p>Hurteau, GJ, <strong>Spivack</strong> <strong>SD</strong>, Brock G.&nbsp; Parallel identification of miRNA and target mRNA by combined informatics and qRT-PCR approaches: application to <em>has-miR-200c.</em>&nbsp; <em>Cell Cycle</em> 5(17):1951-56, 2006.</p>
<p>Han W, Cauchi S, Herman JG, <strong>Spivack SD</strong>.&nbsp; Methylation mapping of DNA by tag-modified bisulfite genomic DNA sequencing. <em>Analytic Biochem. 355: 50-61,</em> 2006.</p>
<p>Cauchi S, Han W, Kumar SV, <strong>Spivack SD</strong>. Haplotype-environment interactions regulating the human <em>GSTP1</em> promoter <em>Cancer Res</em>. 66(12): 6439-6448, 2006.</p>
<p>Kumar SV, Hurteau GJ, <strong>Spivack SD.</strong> Validity of mRNA expression analyses of human saliva. <em>Clin. Cancer Res.</em> 12: 5033-39, 2006.</p>
<p><strong>Spivack SD</strong>, Hurteau GJ, Jain R, Kumar SV, Aldous KM, Gierthy JF, Kaminsky LS.&nbsp; Gene-environment interaction signatures by quantitative mRNA profiling in exfoliated buccal mucosal cells. <em>Cancer Res,</em> 64:6805-6813, 2004.</p>
<p><strong>Spivack SD</strong>, Hurteau GJ, Fasco MJ, Kaminsky LS.&nbsp; Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors.&nbsp; <em>Clinical Cancer Research</em>, 9:6002-6011, 2003.</p>
<p>&nbsp;</p>

EMR ID

4969

Biography

<p>Simon D. Spivack, MD, MPH, is Professor, Medicine, Epidemiology and Genetics at Montefiore Einstein. He is also former Emeritus Chief, Pulmonary Medicine. Clinically, Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease. </p><p>After obtaining his Bachelor of Science in Psychobiology from McGill University in Montreal, Canada in 1980, Dr. Spivack earned his Doctor of Medicine from the State University of New York Upstate Medical University in 1985. He then completed an internship and residency in internal medicine at the University of Massachusetts Medical Center in 1988. Dr. Spivack then earned his Master of Public Health at Harvard University, School of Public Health in 1989. He completed a clinical pulmonary and critical care medicine and lung research fellowship at the University of Vermont in 1992. </p><p>Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans. His work has been published in numerous peer-reviewed journals, articles, chapters and books, and he has given many national/international presentations, organized symposia and visiting professorships. Dr. Spivack is on the Editorial Board for Scientific Reports and is a reviewer for journals such as <em>PLoS Genetics</em>, <em>Genetics in Medicine</em>, <em>Nature Protocols</em>, <em>American Journal of Respiratory &amp; Critical Care Medicine</em>, <em>Carcinogenesis</em>, <em>Cancer Research</em> and others. He holds multiple United States patents. He has been continually funded by the National Institutes of Health (NIH) for research for over 25 years.
</p><p>Dr. Spivack is board certified in internal medicine, pulmonary medicine and critical care medicine. He is a member of the American Thoracic Society (ATS), the American Association for Cancer Research (AACR) and the American Lung Association (ALA). He is a frequent peer-reviewer on various NIH study sections. In the past, Dr. Spivack won the Excellence in Research Award from ALA and the NIH/National Institute of Environmental Health Sciences (NIEHS) Clinical Scientist Development Award.

</p>

Visit Type ID

2542

Is Open Scheduling

On

Zocdoc Link

Stuart Packer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0d90dcb0-3939-11ed-9b41-f32856b0701a.jpg

First Name

Stuart

Last Name

Packer

NPI

1124059621

Faculty ID

13484

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore&rsquo;s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.

Elsevier Profile

EMR ID

5497

Biography

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Is Open Scheduling

Off

Nitin Ohri

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/4a5e97b0-c3cc-11eb-a1b3-af964b18991d.jpg

First Name

Nitin

Last Name

Ohri

NPI

1346499431

Faculty ID

13388

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treating lung and gastrointestinal cancers.

Research Focus

Incorporating novel imaging metrics in the implementation of radiotherapy for non-small cell lung cancer, understanding how physical activity data can be leveraged to enhance the value of cancer care, and exploring novel combinations of immunotherapy and radiotherapy.

Elsevier Profile

EMR ID

5629

Biography

<p>Nitin Ohri, MD, MS, is Professor, Radiation Oncology at Montefiore Einstein. He is a radiation oncologist with a clinical focus on treating lung and gastrointestinal cancers.</p><p>After completing his Bachelor of Science in biomedical engineering at Columbia University in 2003, Dr. Ohri earned his Doctor of Medicine from Washington University in 2007. He then completed an internship in internal medicine at Barnes-Jewish Hospital in 2008 and then participated in a radiation oncology residency at Thomas Jefferson University, completing it in 2012. Dr. Ohri earned his Master's degree from the Clinical Research Training Program at Montefiore Einstein in 2015.</p><p>Building on his clinical focus, Dr. Ohri&rsquo;s research focuses on incorporating novel imaging metrics in the implementation of radiotherapy for non-small cell lung cancer, understanding how physical activity data can be leveraged to enhance the value of cancer care, and exploring novel combinations of immunotherapy and radiotherapy. Dr. Ohri has designed numerous ongoing and completed investigator-initiated trials that test novel functional imaging-based radiotherapy delivery strategies and new combinations of immunotherapy and radiotherapy. He is also leading a series of trials incorporating continuous activity monitoring with wearable devices into the care of cancer patients. The unifying theme of his work is leveraging novel forms of multidimensional data to improve cancer care, and his work has been presented in many peer-reviewed publications and abstracts. Dr. Ohri is a reviewer for multiple journals, such as the <em>International Journal of Radiation Oncology, Biology, Physics</em>, the <em>American Journal of Clinical Oncology</em> and <em>Journal of the National Cancer Institute</em>.</p><p>Dr. Ohri is board certified in Radiation Oncology by the American Board of Radiology and is a member of the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Association for Cancer Research. He has won multiple awards, including numerous &ldquo;Outstanding Reviewer&rdquo; Awards from the <em>International Journal of Radiation Oncology, Biology, Physics</em>, the Cancer Care Delivery Research Pilot Project Award from NRG Oncology and the Fellowship Award from the Empire Clinical Research Investigator Program.</p>

Is Open Scheduling

Off

Balazs Halmos

https://assets.montefioreeinstein.org/profiles/images/Halmos_Balazs_MD_2x.jpg

First Name

Balazs

Last Name

Halmos

NPI

1013933290

Faculty ID

14771

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Balazs Halmos, MD, MS was recruited in May 2015 to serve as Director of the Multidisciplinary Thoracic Oncology Program and Director of the Section of Thoracic Medical Oncology for Montefiore Health Systems. Dr. Halmos has also been appointed as the first Director of Clinical Cancer Genetics and Professor of Clinical Medicine at Einstein.</p>
<p>Dr. Halmos is an authority in the management of patients with malignancies of the thoracic cavity such as lung cancer, gastroesophageal cancer and thymoma. His research interests are focused on studies of targeted agents for the treatment of thoracic malignancies as well as translational studies aimed at different aspects of lung cancer biology such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics. He will oversee the thoracic clinical trials program and spearhead the effort to develop guidelines for genetic testing for cancer patients of different anatomic sites to implement a personalized cancer medicine approach.</p>
<p>Dr. Halmos joined Montefiore and Einstein from Columbia University Medical Center, where he was Director of Thoracic Medical Oncology since 2009, Associate Professor of Medicine, and Chairman of the Cancer IRB. He completed a medical degree summa cum laude from Semmelweis University in Budapest, Hungary, an internal medicine residency at St.Luke&rsquo;s-Roosevelt Hospital/Columbia University, and a hematology/oncology fellowship program at Beth Israel Deaconess Medical Center/Harvard Medical School, where he also obtained a master of science in clinical sciences from Harvard Medical School. Since completion of his fellowship, he has been on the faculties at Harvard, Case Western Reserve University, and Columbia.</p>
<p>Dr. Halmos is the recipient of multiple awards from organizations such as the American Society of Clinical Oncology, American Association for Cancer Research, and American Cancer Society and serves as a permanent review board member for the American Cancer Society. He is board certified in internal medicine and medical oncology.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Halmos is an authority in the management of patients with malignancies of the thoracic cavity such as lung cancer, gastroensophageal cancer and thymoma. His research interests are focused on studies of targeted agents for the treatment of thoracic malignancies as well as translational studies aimed at different aspects of lung cancer biology such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics. He oversees the thoracic clinical trials program and spearheads the effort to develop guidelines for genetic testing for cancer patients of different anatomic sites to implement a personalized cancer medicine approach.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Halmos is a thoracic medical oncologist focused on the management of patients with malignancies of the thoracic cavity, such as lung and gastroesophageal cancers as well as thymoma. He also oversees the thoracic clinical trials program of novel clinical studies at the Albert Einstein Cancer Center and is spearheading the effort to develop a molecular testing paradigm for cancer patients managed within the Montefiore Health System to facilitate a personalized cancer medicine approach throughout the health system.

Research Focus

Dr. Halmos&rsquo; research interests encompass clinical studies of experimental therapeutics, in particular studies of targeted agents for the treatment of thoracic malignancies as well as translational studies focused on different aspects of lung cancer biology, such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation and targeted therapeutics.

Elsevier Profile

EMR ID

33129

Biography

<p>Balazs Halmos, MD received his medical degree summa cum laude from Semmelweis University in Budapest, Hungary. He completed an internal medicine residency program at St.Luke&rsquo;s-Roosevelt Hospital/Columbia University in New York City followed by a hematology/oncology fellowship program at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Massaschuestts.</p><p>While in Dr. Halmos, also obtained an MS degree in Clinical Sciences from Harvard Medical School. Since completion of his fellowship, he has been a faculty member at Harvard, Case Western Reserve University and most recently an Associate Professor of Medicine at Columbia University Medical Center in New York. There he served as Director of Thoracic Oncology from 2009-2014 and was also Chair of the Cancer IRB.</p><p>Dr. Halmos also oversees the thoracic clinical trials program of novel clinical studies at the Montefiore Albert Einstein Cancer Center and is spearheading the effort to develop a molecular testing paradigm for cancer patients managed within the Montefiore to facilitate a personalized cancer medicine approach throughout the health system.</p><p>He is the recipient of multiple awards from prestigious organizations such as the American Society of Clinical Oncology, American Association for Cancer Research and the American Cancer Society, where he also serves as a permanent review board member. </p>

Is Open Scheduling

Off

Rasim A. Gucalp

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e88015b0-09f1-11ed-be8f-e58d49e7c7df.jpg

First Name

Rasim

Last Name

Gucalp

NPI

1295815785

Faculty ID

4777

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Rasim Gucalp&rsquo;s research interests include novel therapies in lung cancer as well as supportive care in cancer patients. He is actively involved in the multidisciplinary care of patients with lung cancer and central nervous system tumors. He is a member of several Montefiore Medical Center/Albert Einstein College of Medicine committees including the institutional tumor board, faculty senate, Pharmacy and Therapeutic Committee, and COGME.</p>
<p>A native of Turkey, Dr. Gucalp received his medical degree at Hacettepe University School of Medicine in Ankara, Turkey. After completing his medical residency at Downstate Medical Center in Brooklyn, he came to Montefiore Medical Center to complete his oncology fellowship. He is the director of the Hematology/Oncology Fellowship Program at Montefiore, and serves as a professor of Clinical Medicine at Albert Einstein College of Medicine.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3765

Is Open Scheduling

Off

Neel P. Chudgar

https://assets.montefioreeinstein.org/profiles/images/Chudgar_Neel_MD_2x.jpg

First Name

Neel

Last Name

Chudgar

NPI

1598022709

Faculty ID

17032

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;">Dr. Chudgar is a thoracic surgeon with a special interest in the treatment of lung and esophageal cancer, as well as malignancies of the mediastinum and chest wall. He is involved in the investigation of incidental lung nodules to ensure potential lung cancers are not lost to follow-up.&nbsp;</span><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

<span style="background-color:#ffffff;">Dr. Chudgar&nbsp;</span><span style="color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;">is involved in the investigation of incidental lung nodules to ensure potential lung cancers are not lost to follow-up. He also has an interest in the biology of early-stage lung cancer to aid in earlier detection.&nbsp;</span>

Elsevier Profile

EMR ID

163558

Biography

<p style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);margin-bottom:0px;color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;"><span style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);">Neel P. Chudgar, MD, is Associate Director of Clinical and Translational Research, Thoracic Surgery, and an Attending Physician at Montefiore. He is also an Assistant Professor of Cardiothoracic and Vascular Surgery at our Albert Einstein College of Medicine.&nbsp;</span></p><p style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);margin-top:2rem;margin-bottom:0px;color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;"><span style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);">Dr. Chudgar received his Bachelor of Arts from Boston University in 2008 and earned his Doctor of Medicine from Renaissance School of Medicine at Stony Brook University in 2012. His postdoctoral training began with a General Surgery residency at NewYork-Presbyterian Hospital, Weill Cornell Medical Center. From 2014 to 2016, he was a research fellow with Memorial Sloan Kettering Cancer Center. In 2021, he completed his Cardiothoracic Surgery fellowship with NewYork-Presbyterian, Weill Cornell and Memorial Sloan Kettering Cancer Center.</span></p><p style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);margin-top:2rem;margin-bottom:0px;color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;"><span style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);">Dr. Chudgar is a thoracic surgeon with a special interest in the treatment of lung and esophageal cancer, as well as malignancies of the mediastinum and chest wall. He is involved in the investigation of incidental lung nodules to ensure potential lung cancers are not lost to follow-up. He also has an interest in the biology of early-stage lung cancer to aid in earlier detection. He is board certified and his work has been shared in many peer-reviewed publications, book chapters and oral presentations.</span></p>

Is Open Scheduling

Off